Diageo plc vs Revvity Inc — how do they compare? Diageo plc trades at $86.52 (market cap $47.67B), while Revvity Inc trades at $154.86 (market cap $16.98B). The key difference: Diageo plc is far larger — about 2.8× Revvity Inc's market cap, and Diageo plc pays the higher dividend (2.3%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Revvity Inc for 12 Days on average.
| DEO | RVTY | |
|---|---|---|
Market Cap | $47.67B | $16.98B |
Volume | 893,372 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $157.36 |
52-Week Low | $72.47 | $82.26 |
Typical Hold Time | 66 Days | 12 Days |
Enterprise Value | $68.09B | $19.30B |
Dividend Yield | 2.3% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.82, up 2.47% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with consistent earnings beats, a 15.82% ROE, and improving cash flow trends. Recent corporate developments include a new CFO appointment and marketing initiatives supporting brand strength amid ongoing US business restructuring.
The outlook remains positive with 49% analyst buy ratings and cost-saving initiatives driving margin improvement. Key risks include US market volatility and regulatory challenges in India. The stock presents a compelling turnaround story with valuation support at current levels.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
Latest headlines on both assets
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →